Corcept Therapeutics Inc., of Menlo Park, Calif., reported 2016 revenue of $81.3 million, up 62 percent over the same quarter in 2015, from sales of Cushing's syndrome drug Korlym (mifepristone). Read More
Tigenix NV, of Leuven, Belgium, said the first patient was enrolled and treated in its phase Ib/IIa trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia. Cx611 is an intravenously administered product of allogeneic expanded adipose-derived stem cells. Read More
Exelixis Inc., South San Francisco, and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, have signed an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis' lead oncology medicine. Read More
Rigel Pharmaceuticals Inc., of South San Francisco, said it priced its public offering of 20 million shares of common stock at $2 apiece for gross proceeds of about $40 million. Rigel granted underwriters a 30-day option to purchase up to an aggregate of 3 million additional shares, which would bring in as much as $6 million more. Read More
LONDON – Following a total corporate makeover and a revamp of its technology, Realm Therapeutics plc has announced its rebirth with the filing of an FDA investigational new drug application (IND) for a phase II study of its lead product, PRO22, in atopic dermatitis and a promise to start a second phase II, in allergic conjunctivitis, later this year. Read More
Science stands "at the very beginning of understanding the complexity" of the gut microbiome, Synthetic Biologics Inc. CEO Jeffrey Riley told BioWorld Today, noting that his company engages in "more traditional drug discovery and development vs. what Seres [Therapeutics Inc.] is doing, which is more on the cutting edge" – an edge where complexity can take its toll. And did. Read More
Shares of Tenax Therapeutics Inc. (NASDAQ:TENX) fell 76.4 percent to 46 cents by Tuesday's close on news that its lead candidate, levosimendan, failed to meet the co-primary endpoints of a phase III study evaluating its potential for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), an indication for which it had been granted FDA fast track status. Read More
In his first official meeting with the biopharma industry, President Donald Trump repeatedly delivered a clear message: Get U.S. drug prices down. Way down. Read More
